VT-122: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

27 March 2024

24 March 2024

  • curprev 05:3405:34, 24 March 2024‎ Lazy talk contribs‎ 1,557 bytes −81‎ No edit summary
  • curprev 05:3205:32, 24 March 2024‎ Lazy talk contribs‎ 1,638 bytes +1,638‎ Created page with "{{TreatmentInfo |drug_name=VT-122 (Propranolol and Etodolac combination) |FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer t..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=VT-122"